These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 22310623)

  • 1. Abrogation of antibodies improves outcome of renal transplantation.
    Trivedi HL; Vanikar AV; Gumber MR; Patel HV; Shah PR; Kute VB
    Transplant Proc; 2012 Jan; 44(1):241-7. PubMed ID: 22310623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
    Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
    Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal deletion using total lymphoid irradiation with no maintenance immunosuppression in renal allograft recipients.
    Trivedi HL; Kaneku H; Terasaki PI; Feroz A; Vanikar AV; Trivedi VB; Khemchandani SI; Dave SD; Modi PR; Jahr F; Idica A; Everly MJ
    Clin Transpl; 2009; ():265-80. PubMed ID: 20524291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abrogation of anti-HLA antibodies via proteasome inhibition.
    Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
    Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desensitization protocol for highly sensitized renal transplant patients: a single-center experience.
    Kute VB; Vanikar AV; Trivedi HL; Shah PR; Goplani KR; Patel HV; Gumber MR; Patel RD; Kanodia KV; Suthar KS; Trivedi VB; Modi PR
    Saudi J Kidney Dis Transpl; 2011 Jul; 22(4):662-9. PubMed ID: 21743208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL; Murillo D
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.
    Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C
    Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. World kidney day 2010: medical aspects of 10 live-donor renal transplantations in a single center from a developing country.
    Shah PR; Modi PR; Kute VB; Vanikar AV; Patel HV; Gumber MR; Shah VR; Trivedi HL
    Transplant Proc; 2012 Jan; 44(1):47-8. PubMed ID: 22310575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
    Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
    Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
    Stuckey LJ; Kamoun M; Chan KM
    Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of human leukocyte antigen, donor-specific antibodies, and their impact in renal transplantation.
    Thiyagarajan UM; Bagul A; Frost J; Horsburgh T; Nicholson ML
    Transplant Proc; 2012 Jun; 44(5):1231-5. PubMed ID: 22663991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Removal of physiologic corticosteroid doses results in HLA antibody appearance and allograft dysfunction in patients transplanted under a clonal deletion protocol.
    Everly MJ; Jahr F; Kaneku H; Trivedi HL; Terasaki PI
    Clin Transpl; 2009; ():281-93. PubMed ID: 20524292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
    Cooper JE; Gralla J; Chan L; Wiseman AC
    Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
    Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M
    Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic analysis of acute vascular rejection cases after renal transplantation.
    Shimizu T; Tanabe T; Omoto K; Ishida H; Tanabe K
    Transplant Proc; 2012 Jan; 44(1):230-5. PubMed ID: 22310621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of transplant outcomes after five or six human leukocyte antigen-mismatched living donor kidney transplantation.
    Lee HS; Kim MS; Kim YS; Joo DJ; Ju MK; Kim SJ; Kim SI; Huh KH; Park K
    Transplant Proc; 2012 Jan; 44(1):273-5. PubMed ID: 22310631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful transplantation across positive B-cell cross-match in deceased donor renal transplants.
    Goh A; Oei E; Vathsala A
    Transplant Proc; 2012 Jan; 44(1):193-9. PubMed ID: 22310613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.